ConductScience.org, home

Paper39963129

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.

Moser LM and 16 others. Front Immunol, 2025. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. Papers, record 39963129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39963129

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
2.63, provisional
iCite
Revised in PubMed
2026-11-04
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moser LMLaura M
2Heim CCatrin
3Koschade SESebastian E
4Wendel PPhilipp
5Bozkurt SSüleyman
6Harenkamp SSabine
7Kreyenberg HHermann
8Merker MMichael
9Münch CChristian
10Gradhand EElise
11Vogler MMeike
12Ullrich EEvelyn
13Bönig HHalvard
14Klusmann JHJan-Henning
15Bader PPeter
16Wels WSWinfried S
17Rettinger EEva

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RhabdomyosarcomaMajor topic
Immunotherapy, AdoptiveMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Cytokine-Induced Killer CellsMajor topic
Receptors, Chimeric AntigenMajor topic
Humans
Animals
Mice
Cell Line, Tumor
Xenograft Model Antitumor Assays
Cytotoxicity, Immunologic
Cytokines
Female

Source PubMed

Download CSV of topics

References74

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132484595Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy.J Cell Physiol2020https://conductscience.org/library/papers/32484595PubMed
216997856Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms.J Leukoc Biol2006https://conductscience.org/library/papers/16997856PubMed
337148198Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.Neuro Oncol2023https://conductscience.org/library/papers/37148198PubMed
423985696Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".Mol Ther2013https://conductscience.org/library/papers/23985696PubMed
534686489CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1.Cancer Immunol Res2021https://conductscience.org/library/papers/34686489PubMed
619375652Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.Exp Hematol2009https://conductscience.org/library/papers/19375652PubMed
736529024A2AR limits IL-15-induced generation of CD39+ NK cells with high cytotoxicity.Int Immunopharmacol2023https://conductscience.org/library/papers/36529024PubMed
835879429Natural killer cells in antitumour adoptive cell immunotherapy.Nat Rev Cancer2022https://conductscience.org/library/papers/35879429PubMed
936634289CAR T-Cells for Cure in Pediatric B-ALL.J Clin Oncol2023https://conductscience.org/library/papers/36634289PubMed
1011342413Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production.Blood2001https://conductscience.org/library/papers/11342413PubMed
1137481241INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.Transplant Cell Ther2023https://conductscience.org/library/papers/37481241PubMed
1229769722Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.Nature2018https://conductscience.org/library/papers/29769722PubMed
1329385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
1422116087The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.Nat Rev Immunol2011https://conductscience.org/library/papers/22116087PubMed
1529029499Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.Oncotarget2017https://conductscience.org/library/papers/29029499PubMed
1631900462'Off-the-shelf' allogeneic CAR T cells: development and challenges.Nat Rev Drug Discov2020https://conductscience.org/library/papers/31900462PubMed
1726768688Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.Haematologica2016https://conductscience.org/library/papers/26768688PubMed
1818565854In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.Blood2008https://conductscience.org/library/papers/18565854PubMed
1933603738Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ γδT Cells a Unique Lymphocyte Subset.Front Immunol2020https://conductscience.org/library/papers/33603738PubMed
2032483603Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.Blood2020https://conductscience.org/library/papers/32483603PubMed

See all 74 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42613325Role of epithelial-mesenchymal transition (EMT) in malignancies: current status and future prospects.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42613325PubMed
42527917Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Mol Cancer2026https://conductscience.org/library/papers/42527917PubMed
41941697First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.J Clin Oncol2026https://conductscience.org/library/papers/41941697PubMed
41394804Current landscape of CAR-therapy for osteosarcoma and rhabdomyosarcoma.Front Immunol2025https://conductscience.org/library/papers/41394804PubMed
41340123Implications of DNA damage response and immunotherapy in tumor therapy.Cell Commun Signal2025https://conductscience.org/library/papers/41340123PubMed
41112277Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival.Front Immunol2025https://conductscience.org/library/papers/41112277PubMed
41038289Towards directed therapy for fusion-positive rhabdomyosarcoma.Pharmacol Ther2025https://conductscience.org/library/papers/41038289PubMed
41007114Tumor-Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies.Children (Basel)2025https://conductscience.org/library/papers/41007114PubMed
40944718Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody.Cancer Immunol Immunother2025https://conductscience.org/library/papers/40944718PubMed
40758198Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer.Clin Exp Med2025https://conductscience.org/library/papers/40758198PubMed
40575784Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions.Front Pharmacol2025https://conductscience.org/library/papers/40575784PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39963129

GET https://conductscience.org/api/papers/v1/39963129/references?page=2